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a  b  s  t  r  a  c  t
Folates  have  been  used  with  cytotoxic  agents  for decades  and  today  they  are  used in hundreds
of  thousands  of patients  annually.  Folate  metabolism  is complex.  In  the  treatment  of cancer  with
5-ﬂuorouracil,  the  administration  of  folates  mechanistically  leads  to  the  formation  of [6R]-5,10-
methylene-tetrahydrofolate,  and  the  increased  concentration  of this  molecule  leads  to  stabilization  ofeywords:
olate metabolism
eucovorin
echanism of action
-Fluorouracil,
6R]-5,10-methylene-tetrahydrofolate
the  ternary  complex  comprising  thymidylate  synthase,  2′-deoxy-uridine-5′-monophosphate,  and  [6R]-
5,10-methylene-tetrahydrofolate.  The  latter  is the  only  natural  folate  that  can bind directly  in  the  ternary
complex,  with  other  folates  requiring  metabolic  activation.  Modulation  of  thymidylate  synthase  activ-
ity  became  central  in the  study  of folate/cytotoxic  combinations  and,  despite  wide  use, research  into  the
folate component  was  neglected,  leaving  important  questions  unanswered.  This  article  revisits  the mech-
anisms  of action  of  folates  and  evaluates  commercially  available  folate derivatives  in the  light  of  current
∗ Corresponding author at: Department of Medical Oncology, VU University Medical Center, P.O. Box 7057, 1007 MB,  Amsterdam, The Netherlands.
E-mail address: GJ.Peters@vumc.nl (G.J. Peters).
ttp://dx.doi.org/10.1016/j.critrevonc.2016.08.001
040-8428/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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research.  Better  genomic  insight  and  availability  of new  analytical  techniques  and  stable  folate  compounds
may open  new  avenues  of  research  and  therapy,  ultimately  bringing  increased  clinical  beneﬁt to  patients.
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. Introduction
Since the 1970s, tetrahydrofolates such as leucovorin have been
sed in combination with antimetabolites for the treatment of
arious malignant diseases. The rationale for including tetrahydro-
olates, often somewhat incorrectly alluded to as just ‘folates’, has
een to reduce side effects (enhance safety) of folate analogs such as
ethotrexate, and/or improve the antimalignant effects (enhance
fﬁcacy) of antimetabolites such as 5-ﬂuorouracil (5-FU) and its
erivatives. The clinical use of tetrahydrofolates has shown no ten-
ency to diminish over time, and they have become an established
omponent of several therapeutic strategies. In some instances,
heir use preceded understanding of, for example, the different
olate derivatives, modes of administration, dose–effect relation-
hips (particularly for multidrug combinations), and necessary
arget organ metabolite concentrations, as well as the development
f precise and direct analytical methods.
The dominating research efforts regarding anticancer com-
inations have been devoted to the cytotoxic or cytostatic
ntimetabolites, and less interest has been paid to the folate
omponent as such. Indeed, much of the folate research was per-
ormed during the 1970s–1990s, but important contributions are
till made, especially regarding the role and importance of subcel-
ular compartmentalization. However, there are still large poorly
nderstood areas, for example differences between physiologi-
al situations and pharmacological conditions when high doses of
olates are administered. It is possible that the role of compart-
entalization is diminished when subcompartmental levels also
ecome inﬂuenced by high pharmacological concentrations, which
s a focus of this paper. In view of the extensive continuing use of
olate derivatives in oncology, the aim here is to review the ﬁeld in
rder to stimulate renewed research interest and to point at infor-
ation gaps, with special relevance for therapeutic applications.
. Chemical structure, transport, and metabolism of folatesLeafy vegetables are the principal nutritional source of folates,
ith the term ‘natural folate’ being used for those folates, and
heir derivatives, that are found in living organisms. All tetrahy-
rofolate structures are built from three units: tetrahydropterin,
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p-aminobenzoic acid, and l-glutamic acid (Fig. 1). Naturally occur-
ring tetrahydrofolates contain two  asymmetric stereocenters. The
chiral C-atom, which is part of the l-glutamic acid moiety, has
the natural [S]-conﬁguration. Due to the ﬁxed asymmetry of
the l-glutamic acid moiety, there are no enantiomers (and no
racemates) among the tetrahydrofolates; only diastereoisomers
exist, which have either the [6R]- or [6S]-conﬁguration at the C-
6 atom. Therefore, when a natural diastereoisomeric form of a
particular tetrahydrofolate is administered, the enzymatic inter-
conversions never change the absolute conﬁguration at the C-6
atom of the tetrahydropterin ring. This chiral form determines and
stays unchanged for all naturally occurring folates, and structurally
also deﬁnes the term ‘natural folates’. However, according to the
[R,S] system of nomenclature, the same absolute conﬁguration at
the C-6 atom may  be named differently from one compound to
another.
There is only one exception to this rule. Although disputed,
a non-enzymatic interconversion has been described for [6R]-
5-formyl-tetrahydrofolate (THF) back to 7,8-dihydrofolate (DHF),
which is non-asymmetric at the C-6 atom (Baggott and Tamura,
1999; Baggott et al., 2001). This interconversion (Fig. 2) may  explain
why an intravenous dose of [6R,S]-5-formyl-THF produces slightly
more bioactive folates than one-half that of [6S]-5-formyl-THF
(DeVito et al., 1993).
Serum folates circulate as monoglutamate derivatives and are
imported into cells through the reduced folate carrier (RFC), the
proton-coupled folate transporter (PCFT), or via folate receptor
(FR)-mediated endocytosis (Qiu et al., 2006; Zhao and Goldman,
2013; Zhao et al., 2009; Chattopadhyay et al., 2007; Desmoulin
et al., 2012). RFC has a preference for reduced folates and is a high-
capacity, low-afﬁnity transporter, whereas FR is a high-afﬁnity,
low-capacity transporter; both RFC and FR have pH optima at phys-
iological levels. PCFT has a low pH optimum (around pH 5.5), can
transport both oxidized and reduced folates and antifolates, and
plays a major role in folate uptake in the gut and in some tumors.
Once in the cytoplasm, folates are processed to metabolic co-
factors by sequential addition of l-glutamic acid residues by the
enzyme folyl-polyglutamate synthetase (FPGS) (Turner et al., 2000;
Rots et al., 1999; Gonen and Assaraf, 2012; Walling, 2006). The
polyglutamate chain comprises up to nine residues linked by
gamma  peptide bonds, and is linked to tetrahydropteroic acid car-
rying one-carbon units of various oxidation levels at the N5 and/or
N10 positions (Fig. 3). The hydrophilic polyglutamate chain serves
both to retain the folate within the cell and to increase the afﬁn-
ity for folate-dependent enzymes (Radparvar et al., 1988; Boarman
and Allegra, 1992; Lawrence et al., 2014). Folate polyglutamates
regulate the rate of reaction of the key metabolic enzymes in
one-carbon metabolism and allow channelling of the substrates
between enzymes (Lawrence et al., 2014; Lowe et al., 1993). FPGS is
located in both the cytosol and mitochondria; however, mitochon-
drial FPGS has a higher speciﬁc activity than cytosolic FPGS, leading
to greater accumulation of folates with a higher chain length in the
mitochondria (Lin et al., 1993). The two pools appear to be com-
partmentalized, meaning that mitochondrial FPGS is required for
maintaining mitochondrial pools and cytosolic FPGS is required for
maintaining cytosolic pools (Anderson et al., 2012).
With synthetic folates that include the same amounts of both the
[6R]- and [6S]-diastereoisomers (e.g. [6R,S]-5-formyl-THF, [6R,S]-
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Fig. 2. Non-enzymatic chemical interconversions for the transformation of [6R]-5-formyl-THF to [6S]-THF. The reaction from [6R]-5-formyl-THF involves chemical oxidation
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ICAR: 5-amino-1-(5-phospho-d-ribosyl)imidazole-4-carboxamide; DHF: 7,8-dihyd
etrahydrofolate.
-methyl-THF, and [6R,S]-5,10-methylene-THF), the unnatural
iastereoisomer will lack the activity of the natural diastereoiso-
er  and will be treated differently in the organism. Indeed, the
nnatural [6R]-isomer of 5-formyl-THF (leucovorin, folinic acid)
as a longer plasma half-life and lower clearance, which may
ead to systemic accumulation (Straw et al., 1984; Newman et al.,
989; Zittoun, 1993; Zittoun et al., 1993), whereas the unnatural
6S]-isomer of 5,10-methylene-THF has been shown to be a rela-
ively weak competitive inhibitor of the [6R]-isomer at the enzyme
hymidylate synthase (TS) (Leary et al., 1974; Cisneros and Dunlap,
990; Sharma and Kisliuk, 1975). However, [6S]-5,10-methylene-
HF is found in plasma only as a result of direct administration of
6R,S]-5,10-methylene-THF, and does not result from administra-
ion of other folates. Furthermore, it has been reported that certain
nnatural folate forms can affect the formation of the ternary
omplex (see Section 5) and, as such, inﬂuence the efﬁcacy of TS
nhibitors (Van der Wilt et al., 1993; Van der Wilt et al., 2002).
. Tetrahydrofolates and their interconversions
There are six known one-carbon-substituted derivatives of [6S]-
HF, each associated with a particular metabolic cycle (Fig. 4)
Jolivet et al., 1996). [6R]-10-formyl-THF is involved in purine syn-
hesis (cycle A), [6R]-5,10-methylene-THF in thymidylate synthesis
cycle B), and [6S]-5-methyl-THF in methionine synthesis (cycle C).
etrahydrofolate derivatives not directly involved in biosynthetic
athways are [6S]-5-formimino-THF, [6R]-5,10-methenyl-THF,23-32 (Baggott and Tamura, 1999).
te; fAICAR: 5-formamido-1-(5-phospho-d-ribosyl)imidazole-4-carboxamide; THF:
and [6S]-5-formyl-THF (levoleucovorin) – all of which are involved
in a ‘futile cycle’ (cycle D) (Jolivet et al., 1996).
The reversible conversion of [6S]-THF and serine to [6R]-5,10-
methylene-THF and glycine, catalyzed by serine hydroxymethyl-
transferase (SHMT), is the primary entry point of one-carbon units
into one-carbon metabolism (Stover and Field, 2011; Locasale,
2013). Notably, however, there is also a non-enzymatic conver-
sion of one-carbon units via a fully reversible chemical reaction:
an acetalisation of [6S]-THF with formaldehyde to form an N,N-
acetal, which is [6R]-5,10-methylene-THF, a reaction that can be
used to synthesize [6S]-5,10-methylene-THF (Moran et al., 1979).
This reaction is known to be highly pH-dependent (Baggott and
Tamura, 1999; Jackson and Harrap, 1973; Spears et al., 1995).
The equilibrium between [6R]-5,10-methylene-THF and [6S]-
THF plus formaldehyde (called ‘instability equilibrium’) is the
reason behind the chemical instability of [6R]−5,10-methylene-
THF. Also, the exceptionally high susceptibility of THF to become
oxidized can drive the equilibrium towards further decomposi-
tion to THF and formaldehyde. Also, other folates (including THF,
DHF, [6S]-5-methyl-THF, and [6R]-10-formyl-THF) are chemically
labile and susceptible to irreversible oxidative degradation. Thus,
in vitro in solution, tetrahydrofolate has a half-life of minutes in
the absence of reducing agents such as thiols and ascorbate, yet
the mean residency time of whole-body folate in humans is much
longer, due to polyglutamylation of several intermediates that are
formed when an exogenous source such as leucovorin is admin-
istered to individuals (Stover and Field, 2011; Allegra and Voeller,
1993; Goldman and Matherly, 1987; Cook et al., 1987). The exact
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etention time is not known, but indirect evidence for a long reten-
ion of polyglutamylated intermediates has been obtained from
tudies with folate analogs, such as lometrexol, which was  retained
or a long period in several organs (e.g. the liver), leading to delayed
oxicity several months after administration (Habeck et al., 1998;
aohavinij et al., 1996). Folates are also stabilized and protected
rom oxidation when bound to cellular proteins, which regulate
olate availability in the cell. While proteins bind folate co-factors
ith dissociation constants in the nanomolar range, folate enzymes
re present in the micromolar range in liver cells (Suh et al., 2001;
adhukar et al., 2015). This means that cellular folates are pro-
ein bound, with limited opportunity to accumulate in the cellular
ilieu (Stover and Field, 2011).
. Key role of [6R]-5,10-methylene-THF
[6R]-5,10-methylene-THF is the key endogenous one-carbon
onor and a co-substrate of the TS enzyme for methylation of 2′-
eoxy-uridine-5′-monophosphate (dUMP) to 2′-deoxy-thymidine-
′-monophosphate (dTMP). This product is one of the necessary
ucleotide substrates for DNA synthesis and repair, and is thus
ssential for cell division and life. Indeed, the widely used antitu-
or  agent 5-FU is known to exert its cytotoxic activity, to a major
xtent, through inhibition of the TS enzyme. Importantly, for either
ynthesis of dTMP, via TS catalysis, or inhibition of TS, by 5-FU, a
ernary complex is formed between TS, [6R]-5,10-methylene-THF,
nd the respective third component, either dUMP or 5-ﬂuoro-2′-
eoxy-uridine-5′-monophosphate (5-FdUMP; Fig. 5).
In vivo, [6R]-5,10-methylene-THF is the only folate that is a
irect component of the ternary complex, together with TS and
UMP or 5-FdUMP: of the two diastereoisomers, only [6R]-5,10-
ethylene-THF is the active form (Leary et al., 1974). Indeed, the
ork by Galivan et al. became ground-breaking in the area of
symmetry and stereoisomerism requirements in relation to the
ernary complex (Galivan et al., 1975). As co-substrate, [6R]-5,10-
ethylene-THF fulﬁls all the highly speciﬁc chemical characteristic
equirements for transfer of the one-carbon unit in this catalytic
rocess. With its N-CH2-N structural moiety, being a masked
ormaldehyde, it is the only natural folate that could have the
mportant ability to get its one-carbon unit in equilibrium with a
ationic species (=N(+) = CH2). Such a highly reactive electrophile is
robably necessary to obtain the crucial attack from the relatively
eakly anionic ‘active methylene’, being the C-5 atom in dUMP. The
-5 atom ‘active methylene’ in the uracil moiety obtains a weakly
nionic character because of an attack on the C-6 atom in uracil by
he sulfhydryl group in TS. All this, together with a speciﬁc hydride
H−) transfer reaction from THF to ﬁnalize the methyl group in thelogy/Hematology 106 (2016) 118–131
thymidine moiety, and a simultaneous formation of DHF, which is
reused, makes it a remarkable phenomenon created during evo-
lution. [6R]-5,10-methylene-THF is a ‘central’ intermediate among
the natural folates undergoing the various one-carbon interconver-
sions. Its one-carbon unit has the oxidation state of formaldehyde
(HCHO), between formic acid (HCOOH) and methanol (CH3OH)
(Stover and Field, 2011).
5. The ‘ternary complex’—a central chemical phenomenon
for life
The concept of the ternary complex, formed by the substrate
dUMP, the TS enzyme, and the co-substrate [6R]-5,10-methylene-
THF, was  put forward over 40 years ago (Langenbach et al., 1972;
Santi, 1972). The theory has not been altered or contradicted in
any signiﬁcant way  since then. The ternary complex comprising
5-FdUMP, instead of dUMP, subsequently became important as a
tool for further study; the F-atom, instead of the H-atom in uracil,
eliminates a crucial proton abstraction in the reaction from dUMP
to dTMP. The biosynthesis of dTMP from dUMP takes place in all
cells and is a vital component of DNA synthesis. It proceeds via
the ternary complex, the formation of which drives the reductive
methylation process. Not unexpectedly, the ternary complex seems
to be conserved in nearly all living species. Indeed, TS has been puri-
ﬁed, crystallized, and the structure determined in the bacterium
Lactobacillus casei (Hardy et al., 1987) as well as in humans (Schiffer
et al., 1995). Furthermore, TS has also been shown to be coded for
in many viruses (Stroud and Finer-Moore, 1993).
5.1. Formation—the chemical mechanism
The formation mechanism can be divided into four events
(Fig. 6) (Carreras and Santi, 1995).
1. The C-5 position of dUMP is activated by the TS enzyme attacking
the C-6 position with a thiol group. This is a well-known reaction
in organic chemistry (i.e. ‘Michael Addition’ of an alpha, beta-
unsaturated ketone). This converts the C-5 position of dUMP to
an active anionic enolate form (I).
2. There is simultaneous activation of [6R]-5,10-methylene-THF by
opening of the 5-membered imidazolidine ring to give iminium
ion formation that includes the CH2-folate carbon (i.e. +N CH2).
The CH2-folate moiety with its two nitrogens is in equilibrium
with the (probably transient) 5-iminium moiety being a highly
reactive cationic nucleophile acceptor.
3. The C-5 enolate anion (I) in the activated dUMP attacks the 5-
iminium CH2 in the folate, forming a methylene bridge between
the dUMP moiety and the folate moiety [i.e. the ternary com-
plex (II)]. The corresponding complex with 5-FdUMP, instead of
dUMP, has been isolated, and nuclear magnetic resonance and
X-ray studies have conﬁrmed the chemical structure. With 5-
FdUMP, however, the further reaction to dTMP is not possible
because, unlike the H-atom, the F-atom cannot be abstracted.
4. The [6S]-THF part is eliminated under formation of the inter-
mediate III, followed by reduction of the one-carbon unit by H−
(hydride ion) transfer from [6S]-THF. The latter then provides
dTMP as the product and DHF as the by-product.
5.2. Covalent but reversible binding
The ternary complex is built by covalent bonds between
the components, and the reactions are fully reversible (Cisneros
and Dunlap, 1990; Stroud and Finer-Moore, 1993; Santi et al.,
1974; Lockshin and Danenberg, 1981; Sato et al., 1986; Spears
et al., 1989; Matthews et al., 1990; Rode, 1993; Jarmuła et al.,
2005). Thus, in a human cell preparation study, both 5-FdUMP
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Spears et al. support the theory of an ordered mechanism, stat-
ing that the concentration of [6R]-5,10-methylene-THF must bend [6R]-5,10-methylene-THF were shown to be dissociable
Lockshin and Danenberg, 1981), and the TS enzyme from
ertain human leukemic cells regained the capacity to syn-
hesize dTMP if excess dUMP was present. Importantly, by
ncreasing the concentration of the [6R]-5,10-methylene-THF
o-substrate, dissociation from the TS − 5-FdUMP − [6R]-5,10-
ethylene-THF[6R]-5,10-methylene-THF ternary complex was
arkedly diminished. On the contrary, the concentration of 5-
dUMP had no effect on the dissociation of the co-substrate. These
bservations are in accordance with a proposed ordered mecha-
ism of ligand release and binding, since the co-substrate has to be
issociated prior to 5-FdUMP release (Danenberg and Danenberg,
978). These data are in line with the ‘principle of microscopic
eversibility’, whereby 5-FdUMP must bind to the enzyme ﬁrst, fol-
owed by the [6R]-5,10-methylene-THF co-substrate. The reverse
eaction must then start with the folate, as shown below (Lockshin
nd Danenberg, 1981).ride ion) transfer from [6S]-THF. The latter then provides dTMP as the product and
-uridine-5′-monophosphate; THF: tetrahydrofolate; TS: thymidylate synthase.
Once formed, the ternary complex containing 5-FdUMP is quite
stable for long periods, provided that excess [6R]-5,10-methylene-
THF is present and the temperature does not exceed 37 ◦C. Indeed,
the ternary complex can be isolated in vitro using Sephadex G-25
gel ﬁltration. It is seen that, at equilibrium, the free and bound
components undergo numerous association − dissociation events
without apparent structural changes. However, degradation occurs
when the complex is freed of unbound [6R]-5,10-methylene-THF
by gel ﬁltration, possibly due to oxidative degradation of the small
amount of [6R]-5,10-methylene-THF present, and its replenish-
ment results in rebinding of [3H]5-FdUMP to the enzyme (Santi
et al., 1974).
5.3. Role of intracellular folate pools in the formation and
stability of the ternary complexin excess for maximal formation of the TS − 5-FdUMP − [6R]-5,10-
methylene-THFR ternary complex and complete inhibition of TS
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ctivity (Spears et al., 1995). In particular, a high concentration of
UMP may  lead to poor TS inhibition by 5-FdUMP when the [6R]-
,10-methylene-THF concentration is low. Hence, for anticancer
herapy, there is a need for increased concentrations of intratu-
oral [6R]-5,10-methylene-THF (Spears et al., 1995), which will
irect the competitive binding between 5-FdUMP and dUMP in
he ternary complex to favor 5-FdUMP (Lockshin and Danenberg,
981).
The total concentration of [6R]-5,10-methylene-THF plus [6S]-
HF in cells is estimated to be 3 M or less, although several
eports give concentrations in terms of pmol/mg protein, which
equires a conversion factor that is not always supplied by the
uthors. As [6R]-5,10-methylene-THF also serves as the substrate
or other enzymes (e.g. it is the precursor for [6S]-5-methyl-THF),
he overall concentration available for TS may  be less than 1 M
Lockshin and Danenberg, 1981). Indeed, in cancer biopsy tissues,
aif et al. reported [6R]-5,10-methylene-THF levels of 0.1–0.5 M
nd lower (Saif et al., 2010), which has also been shown by oth-
rs (e.g. (Priest et al., 1991; Porcelli et al., 2011)). However, it is
roposed that maximum ternary complex formation is generally
chieved at [6R]-5,10-methylene-THF concentrations approaching
2 M (Strohle et al., 2005), and that high intratumoral levels of
6R]-5,10-methylene-THF allow for greater TS inhibition, which is
lso prolonged. It is important to note that these results do not
onsider differences between intracellular compartments.
Chéradame et al. measured reduced folate levels in tumor types
onsidered to be sensitive to 5-FU treatment and observed large
nterpatient variation (Chéradame et al., 1997a). However, [6R]-
,10-methylene-THF levels in the 96 tumor samples (50 head and
eck, 16 colon, 30 liver metastases from colorectal cancer) were
enerally sufﬁciently high enough to sustain 5-FU-mediated TS
nhibition (Chéradame et al., 1997a). Dohden et al. also observed
arge interpatient variation in the pools of [6R]-5,10-methylene-
HF in tumors of patients with colorectal and gastric cancers
Dohden et al., 1993). High folate concentrations were maintained
etter in patients with high FPGS activity, since FPGS served to
orm polyglutamates, which became trapped in cells due to their
ncreased polarity.
Administration of leucovorin in combination with a thera-
eutic dose of 5-FU in patients with colorectal cancer not only
ncreased [6R]-5,10-methylene-THF levels several-fold (Porcelli
t al., 2011), but also maintained TS inhibition after 48 h at
5%, compared with 50% inhibition when 5-FU was adminis-
ered alone (Peters et al., 1994). In addition, in another study in
atients with head and neck cancer, Chéradame et al. reported that
reatment with leucovorin enhanced the concentrations of [6R]-
,10-methylene-THF (Chéradame et al., 1997b); likewise, Dohden
t al. observed a 2 − 3-fold increase in [6R]-5,10-methylene-THF 3 h
fter the administration of 15 mg  leucovorin (Dohden et al., 1993).
rave et al. demonstrated that the increase in tissue [6R]-5,10-
ethylene-THF levels was schedule-dependent (Trave et al., 1988):
 classical 2-h infusion of 500 mg/m2 leucovorin increased [6R]-
,10-methylene-THF levels 5 − 12-fold in seven patients, whereas
 long infusion only increased [6R]-5,10-methylene-THF levels up
o twofold. Chéradame et al. also showed that the patients (n = 12)
ho had a complete response to 5-FU-based therapy had a signif-
cantly higher distribution of [6R]-5,10-methylene-THF than those
n = 29) with either a partial response or no response (Chéradame
t al., 1997b).
Preclinical data have shown that polyglutamate formation is
ssential for the maintenance of reduced folate pools (Houghton
t al., 1994). This was observed in the study by Chéradame et al.
Chéradame et al., 1997a), and explains the maintenance of high
evels of reduced folates in other studies (Strohle et al., 2005). How-
ver, recent ﬁndings from patients with colorectal cancer have
hown large interpatient variability in tissue folate levels afterlogy/Hematology 106 (2016) 118–131
supplementation with leucovorin at standardized dosage (Taﬂin
et al., 2014). High leucovorin doses were needed to exceed baseline
[6R]-5,10-methylene-THF values, particularly in patients with rec-
tal cancer. The results indicate that standardized leucovorin doses
might be insufﬁcient to attain the full antitumor effect of 5-FU for
all patients. Furthermore, it has been suggested that direct adminis-
tration of [6R]-5,10-methylene-THF allows for greater TS inhibition
((Saif et al., 2010) and references cited therein). In a randomized
comparison of equimolar intravenous bolus doses of levoleucov-
orin or [6R]-5,10-methylene-THF, the mucosal and tumor tissue
levels of [6R]-5,10-methylene-THF were several-fold higher after
direct administration of [6R]-5,10-methylene-THF than after lev-
oleucovorin administration (Wettergren et al., 2015).
Considering the subcompartmental level, the dissociation reac-
tion is fully reversible, releasing free [6R]-5,10-methylene-THF,
which can either re-attack the resulting binary complex in the
reversible reaction or stay in solution. Thus, the higher its con-
centration in solution, the easier [6R]-5,10-methylene-THF can
re-attack. For this reason, an increased [6R]-5,10-methylene-THF
concentration will counteract dissociation. With high enough con-
centrations of [6R]-5,10-methylene-THF, the ternary complex can
be expected to be fairly stable, which is the ultimate goal for opti-
mizing the cytotoxic effect of 5-FU. If high plasma concentrations
of [6R]-5,10 −methylene-THF can be maintained, it is reasonable
to believe that cellular concentrations, including tumor concen-
trations, can also be kept high. However, maintenance of high
[6R]-5,10-methylene-THF levels in the tumor are predominantly
dependent on the capability of the tumor to polyglutamate reduced
folates, as these polyglutamates are too polar to efﬂux from the cell.
This possibly explains high [6R]-5,10-methylene-THF levels in the
tumor 48 h after a 2-h infusion of leucovorin (Porcelli et al., 2011).
To summarize, there is extensive, detailed, chemical evidence
for the mechanism of formation of the ternary complex, both for
5-FdUMP and dUMP together with TS and [6R]-5,10-methylene-
THF, which is the only known natural tetrahydrofolate that has
the ability to bind and perform the known reactions. Indeed,
[6S]-5-formyl-THF and [6S]-5-methyl-THF do not have the correct
oxidation states, [6S]-THF does not have the one-carbon unit, and
all other tetrahydrofolates need to be transformed to [6R]-5,10-
methylene-THF.
6. Compartmentation of folate biosynthetic pathways
Folate co-factors have been identiﬁed in all subcellular
organelles, but the highest concentrations are found in the
cytoplasm and mitochondria. This metabolic compartmentation
requires trafﬁcking of folate metabolites along intercompartment
pathways between, for example, the cytoplasm, nucleus, and
mitochondria. Much detail regarding the relative function and
importance of the different compartments remains to be under-
stood. Mitochondria contain as much as 40% of total cellular folates,
and the mitochondrial folate polyglutamates constitute a dis-
tinct pool not in equilibrium with folate polyglutamates in the
cytoplasm (Stover and Field, 2011). Mitochondrial and cytosolic
FPGS maintain the subcellular compartmentation of folates, as no
exchange of polyglutamates takes place over the mitochondrial
membrane (Lawrence et al., 2014). Monoglutamated [6R]-5,10-
methylene-THF is transported across the mitochondrial membrane
by the mitochondrial folate transporter, which is a member of
the mitochondrial carrier family and is responsible for trafﬁck-
ing of the reduced folates over this membrane (Lawrence et al.,
2011). Eukaryotic one-carbon metabolism occurs in two  paral-
lel processes, one cytosolic and one mitochondrial (Tibbett and
Appling, 2010). The one-carbon units generated in the mitochon-
dria, for example from serine, glycine, and formate, are fed from
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he mitochondria into the cytosol (Barlowe and Appling, 1988).
ompartmentation of folates speciﬁcally in tumor tissue and mito-
hondria can be explained by both the higher activity of FPGS
n tumor tissue compared with normal tissue, and by the higher
xpression of FPGS in mitochondria compared with the cytoplasm
Lin et al., 1993).
Folate metabolism per se has always been considered complex,
ith many loops, interdependencies, and mechanisms of active
egulation. Advanced analytical techniques, for example those
ased on liquid chromatography and tandem mass spectrometry,
ave been combined with sophisticated mathematical modelling in
fforts to assess numerous factors simultaneously. Metabolic ﬂux
tudies and metabolomics have begun to illuminate details and sug-
est different interpretations of known facts (Madhukar et al., 2015;
an et al., 2014).
The total folate pool is necessarily limited and de novo
urine biosynthesis, de novo dTMP biosynthesis, and homocysteine
emethylation compete for the folate co-factors. This metabolic
ompetition is particularly relevant for [6R]-5,10-methylene-THF
etween de novo dTMP biosynthesis and homocysteine remethy-
ation (Stover and Field, 2011). Since [6R]-5,10-methylene-THF is
lso a key metabolite for the conversion to [6S]-5-methyl-THF,
6R]-5,10-methenyl-THF, and further to [6R]-10-formyl-THF and
urines, the [6R]-5,10-methylene-THF co-substrate has a particu-
arly central role in cellular folate interconversions (Fig. 7).
The folate-dependent de novo synthesis of dTMP from dUMP,
nvolving the TS enzyme, is also dependent on the SHMT,
ethylene-tetrahydrofolate dehydrogenase (MTHFD), and dihy-
rofolate reductase (DHFR) enzymes. However, isotope tracer
tudies have demonstrated that [6R]-5,10-methylene-THF gen-
rated by SHMT is preferentially incorporated into dTMP
ompared with [6R]-5,10-methylene-THF generated by MTHFD.
his preferential incorporation into dTMP is consistent with com-
artmentation of SHMT with TS, subsequently shown to involve
ell-cycle-dependent nuclear localization of SHMT, TS, and DHFR.
he concept of nuclear one-carbon metabolism was presented
ome 40 years ago in 1976 (Shin et al., 1976). More recent stud-
es have demonstrated that mouse liver nuclei can synthesize
TMP from serine, indicating that nuclei contain the entire folate-
ependent de novo dTMP pathway (Anderson et al., 2012; Anderson
nd Stover, 2009); SHMT, TS, and DHFR have also been found in
uclei isolated from mouse liver (Stover and Field, 2011). Fur-
hermore, several immunohistochemical studies have consistently
hown the presence of TS in the nucleus (Van Triest et al., 2000;
issoon-Haqqani et al., 2006).
. Regulation of folate biochemical pathways
Active transport of folates into the nucleus may  not be required
ecause the nuclear membrane breaks down and reassembles with
ach cell division, offering the opportunity for folate co-factors to be
xchanged between the cytoplasm and nucleus during each mitotic
vent; this includes [6S]-5-methyl-THF, which is the predominant
orm of folate in the cytoplasm. However, only [6S]-THF, DHF,
nd [6R]-5,10-methylene-THF are involved in the dTMP biosyn-
hesis pathway, whereas [6S]-5-methyl-THF is a potent inhibitor of
HMT (the enzyme bringing the methylene group into THF) (Stover
nd Field, 2011; Stover and Schirch, 1991). Being both the pre-
ominant folate in the cytoplasm and a potent inhibitor of SHMT,
6S]-5-methyl-THF may  therefore autoregulate biosynthesis of the
entral intermediate [6R]-5,10-methylene-THF. This means that by
ncreasing ﬁrstly plasma, and secondly cellular, concentrations of
6S]-5-methyl-THF there is the potential to downregulate the cyto-
lasmic concentration of [6R]-5,10-methylene-THF by inhibiting
ts biosynthesis. [6S]-5-formyl-THF is also an effective inhibitor oflogy/Hematology 106 (2016) 118–131 125
SHMT and may  likewise be important in regulating the major entry
point of one-carbon units (Stover and Schirch, 1991).
To summarize, the high afﬁnity of both [6S]-5-methyl-THF and
[6S]-5-formyl-THF for the SHMT enzyme and their high concen-
trations in the cell suggest that these co-factors are capable of
regulating the activity of SHMT in vivo (Stover and Schirch, 1991).
Furthermore, [6S]-5-methyl-THF is formed by reduction of [6R]-
5,10-methylene-THF by the enzyme methylene-tetrahydrofolate
reductase (MTHFR), an essentially irreversible reaction in vivo. The
enzyme is strongly, but slowly, inhibited by S-adenosylmethionine.
Regulation of this enzyme is critical to one-carbon homeostasis, as
[6S]-5-methyl-THF is committed towards methionine biosynthe-
sis, whereas unnecessary accumulation of this co-factor results in
depletion of the one-carbon folate pool and increased inhibition
of SHMT (Stover and Schirch, 1991). Low response to 5-FU plus
leucovorin therapy in some patients has also been linked to low
expression of identiﬁed folate-associated genes (Wettergren et al.,
2014).
8. Folates in clinical use/development − important
biochemical aspects
Folates in clinical use or in development are shown in Table 1.
CoFactor®, leucovorin, and mefolinate are 1:1 mixtures of their
respective [6R]- and [6S]-diastereoisomeric forms. Modufolin®
(Merck & Cie, Schaffhausen, Switzerland), levoleucovorin (Fusilev®,
Spectrum Pharmaceuticals, Inc., Irvine, CA, USA), and Metafolin®
(Merck & Cie, Schaffhausen, Switzerland) are single and natural
diastereoisomers. Although the natural diastereoisomeric forms
of N10-unsubstituted THF (i.e. 5-formyl- and 5-methyl-THF) have
the [6S]-conﬁguration and Modufolin® has the [6R]-conﬁguration,
their stereochemistry or absolute conﬁguration at the C-6 atom are
all the same (nomenclature rules; see Section 2).
8.1. Folic acid
Folic acid (vitamin B9, pteroyl-l-glutamic acid) is a synthetic
compound that itself is not active in humans, but is converted in
the liver to the biologically active DHF, which has no asymme-
try in the pteroyl part (see Section 2). DHF is reduced further in
the body by DHFR to exclusively form [6S]-THF (Walling, 2006;
Tedeschi et al., 2013; Bertino, 1993). This chiral form then stays
unchanged. Folic acid is used in conjunction with cytostatics less
so than leucovorin, but one example of folic acid use is co-treatment
with pemetrexed (Alimta®, Eli Lilly, Indianapolis, IN, USA) to reduce
toxicity. This essential role of folic acid to selectively protect normal
cells was  initially shown in mice; it was demonstrated that the dose
of pemetrexed could be increased safely when folic acid was admin-
istered before and during pemetrexed therapy (Worzalla et al.,
1998; van der Wilt et al., 2001). Furthermore, a randomized clini-
cal study comparing pemetrexed plus cisplatin with cisplatin alone
showed an unpredictably variable and severe toxicity that was
reduced when pemetrexed was combined with folic acid, which
also increased survival in these patients (Vogelzang et al., 2003).
Although it has been suggested by several authors that folic acid
could replace leucovorin in 5-FU modulation, it is unlikely to play
such a role (Houghton et al., 1994). Folic acid is an oxidized folate
that does not increase the concentration of [6R]-5,10-methylene-
THF to that required to enhance FdUMP-mediated inhibition of
TS, and it is unable to modulate 5-FU cytotoxicity at physiologi-
cal concentrations (Houghton et al., 1994). Moreover, in humans,
administration of folic acid at doses above 1 mg/kg leads to accumu-
lation of unmetabolized folic acid in plasma, but it is inefﬁcient at
increasing plasma THF and 5-methyl-THF levels (Bailey and Ayling,
2009; Obeid et al., 2011). Saturation of DHFR seems to occur at
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Fig. 7. Compartmentation of biosynthetic pathways. The intermediate metabolic reactions in the cytoplasm and nucleus, respectively.
Modiﬁed with permission from Stover PJ, Field MS.  Adv Nutr 2011;2:325-31 (Stover and Field, 2011).
AdoHcy: S-adenosylhomocysteine; AdoMet: S-adenosylmethionine; ADP: adenosine diphosphate; ATP: adenosine triphosphate; DHF: 7,8-dihydrofolate; DHFR: 7,8-
dihydrofolate reductase; dTMP: 2′-deoxy-thymidine-5′-monophosphate; dUMP: 2′-deoxy-uridine-5′-monophosphate; MTHFD: methylene-tetrahydrofolate dehydrogenase;
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pTHFR:  methylene-tetrahydrofolate reductase; MTR: methionine synthase; NADP
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lasma folic acid concentrations above 5 nmol/l, resulting in a
lateau of both THF and 5-methyl-THF. Folic acid cannot therefore
e considered an alternative to reduced folates when an increase
f 5,10-methylene-THF is desired.
.2. [6R,S]-5-formyl-THF (leucovorin) and [6S]-5-formyl-THF
levoleucovorin; Fusilev®)
Leucovorin ([6R,S]-5-formyl-THF) has been used for many
ears as rescue treatment to prevent toxicity following high-dose
ethotrexate therapy, and to modulate the cytotoxicity of 5-
U, and is the most widely used folate in the clinical setting. In
oth experimental systems and clinical trials, leucovorin has been
eported to enhance the antitumor activity of 5-FU, due to expan-
ion of the intracellular reduced folate pool, leading to stabilization
f the 5-FdUMP − TS − folate ternary complex. More recently, the
ure active (and natural) diastereoisomer levoleucovorin ([6S]-5-
ormyl-THF) has been developed and used clinically, showing the
ame efﬁcacy and tolerability proﬁles as leucovorin (Kovoor et al.,
009). In this review, randomized and non-randomized studies,
redominantly in colon and rectal tumors, have been compared,inamide adenine dinucleotide phosphate; NADPH: reduced nicotinamide adenine
; TS: thymidylate synthase.
as have schedules utilizing 5-FU alone and 5-FU in combination
with other drugs such as irinotecan and oxaliplatin. In all stud-
ies, formulations of the [6R,S]-mixture and levoleucovorin showed
comparable clinical efﬁcacy.
When 5-FU is given in combination with leucovorin, conver-
sion of leucovorin to the metabolite [6R]-5,10-methylene-THF is
responsible for the enhanced antitumor effects of 5-FU (Advanced
colorectal cancer meta-analysis project, 1992; Meta-Analysis
Group in Cancer et al., 1998). The proposed biochemical basis for
this improvement is the metabolic conversion of the parent leu-
covorin to [6R]-5,10-methylene-THF, which in turn stabilizes the
ternary complex with 5-FdUMP and TS, leading to depletion of
thymidylate required for DNA synthesis.
Studies of intravenous leucovorin previously used indirect
methods for determining [6R]-5,10-methylene-THF (Priest et al.,
1991; Straw and Newman, 1988). After oral administration, the
[6R]-5,10-methylene-THF plus [6S]-THF concentration is about
100 nM;  after intravenous and oral administration, [6R]-10-formyl-
THF, [6R]-5,10-methylene-THF, and [6S]-THF exhibit peak levels
earlier and are eliminated more rapidly than [6S]-5-methyl-THF.
Accumulation of all metabolites after intravenous administra-
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tion is linearly dose-dependent, while oral administration results
in saturation. In order to reach plasma levels high enough
to enhance the effect of 5-FU, intravenous administration is
advocated. More recently, direct biochemical determination of
[6R]-5,10-methylene-THF has become possible, and intravenous
bolus administration is shown to give higher exposure and tissue
concentrations when compared with levoleucovorin (Wettergren
et al., 2015).
The reported enhancement of cytotoxicity by leucovorin
([6R,S]-5-formyl-THF) and mefolinate ([6R,S]-5-methyl-THF) has
focused attention on these two  folates as precursors of [6R]-5,10-
methylene-THF in tumor tissue. Host metabolism of leucovorin,
yielding [6R]-5,10-methylene-THF in the circulatory system, could
also play a role in elevating levels of the active metabolite at
the tumor site. Indeed, metabolism of leucovorin takes place at
more than one site, rather than in a single organ (Priest et al.,
1991). Red blood cells have been reported to metabolize leucovorin
in vitro, giving rise to the same reduced folates as those observed
in vivo. For leucovorin metabolism, it has been suggested that [6R]-
5,10-methylene-THF, [6S]-THF, and [6R]-10-formyl-THF occur in
plasma as intermediates, and are further metabolized to [6S]-5-
methyl-THF. A probable sequence of metabolic steps, leading from
leucovorin to [6S]-5-methyl-THF, is as follows (Straw et al., 1984;
Priest et al., 1991):
[6S]-5-formyl-THF → [6R]-5, 10-methenyl-THF
→ [6R]-10-formyl-THF → [6S]-THF
→ [6R]-5,  10-methylene-THF → [6S]-5-methyl-THF
[6S]-5-methyl-THF is the major, and virtually the only, metabo-
lite found in human plasma and urine after [6S]-5-formyl-THF
metabolism (usually over 95% (Baggott and Tamura, 1999)). Alter-
natively, [6R]-5,10-methenyl-THF can also be directly metabolized
to [6R]-5,10-methylene-THF by the MTHFD enzyme (Pawelek and
MacKenzie, 1998).
As well as being highly dependent on the mode of admin-
istration (with intravenous administration resulting in lower
conversion of leucovorin to [6S]-5-methyl-THF than oral admin-
istration), the bioconversion process is also saturable (with a lower
proportion of leucovorin converted to [6S]-5-methyl-THF at higher
intravenous doses compared with lower doses). In addition, the
plasma half-lives of both [6S]-5-formyl-THF and [6S]-5-methyl-
THF are considerably longer at higher doses (Borsi et al., 1990). Borsi
et al. suggested that constant rate infusion of high leucovorin doses
could signiﬁcantly expand the intracellular pool of active folates;
however, only a twofold increase of [6R]-5,10-methylene-THF con-
centration was  observed in tumor tissue after continuous infusion,
compared with an eightfold increase after a bolus injection of
the same dose (500 mg/m2) (Borsi et al., 1990). In tumor tissues,
though, the folate concentration may  be increased for a prolonged
period (Porcelli et al., 2011). Practical intravenous administration
relies on either bolus injection or infusion over various times peri-
ods, and the impact of these different administrations on absolute
intratissue levels, proportion of patients treated in whom high
tissue levels are reached, and the importance of tissue levels for
therapeutic response all require further clariﬁcation (Wettergren
et al., 2015).
8.3. [6S]-5-methyl-THF (Metafolin®) and [6R,S]-5-methyl-THF
(mefolinate)Metafolin® ([6S]-5-methyl-THF), the natural diastereoisomeric
form, is the folate normally found in the circulation and is also the
predominant folate present in food. It is available commercially
1 n Oncology/Hematology 106 (2016) 118–131
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oth as the natural form and as mefolinate, the diastereoisomeric
:1 mixture [6R,S]-5-methyl-THF. The MTHFR enzyme is responsi-
le for the irreversible reduction of [6R]-5,10-methylene-THF to
6S]-5-methyl-THF. This folate is needed for the biosynthesis of
ethionine from homocysteine via donation of the methyl group
s a one-carbon unit. There is a genetic polymorphism associated
ith human MTHFR enzyme activity, and decreased plasma activity
f MTHFR is associated with low plasma [6S]-5-methyl-THF con-
entration and elevated levels of homocysteine (Prinz-Langenohl
t al., 2009).
Studies in humans have shown that administration of
etafolin® is at least as effective as folic acid at increasing both
he plasma folate area under the curve and red blood cell folate
evels, and at lowering homocysteine levels. This may  mean higher
elative bioavailability of [6S]-5-methyl-THF when compared with
dministration of folic acid (Prinz-Langenohl et al., 2009; Lamers
t al., 2004; Lamers et al., 2006).
Similar therapeutic beneﬁt has been reported with single intra-
enous administrations of mefolinate or leucovorin in combination
ith 5-FU for the treatment of colorectal cancer ((Mader et al.,
995) and references cited therein). Administration of 200 mg/m2
f either mefolinate or leucovorin resulted in a threefold elevation
f [6R]-5,10-methylene-THF for both agents. Similar plasma con-
entration − time proﬁles were found, with faster elimination from
he blood and higher renal clearance of the [6S]- compared with the
6R]-isomer. Intratumoral folate levels were also shown to be the
ame.
.4. [6R,S]-5,10-methylene-THF (CoFactor®)
CoFactor® ([6R,S]-5,10-methylene-THF), a 1:1 mixture of the
wo diastereoisomers, is very sensitive to oxygen (Odin et al., 1998).
s the [6R]-isomer is the directly active co-substrate of TS, it was
nticipated that administration of CoFactor®, rather than leucov-
rin, would be advantageous due to lower inter- and intrapatient
ariability regarding both clinical safety and efﬁcacy. However, the
nnatural [6S]-isomer is a partial competitive inhibitor of the nat-
ral [6R]-isomer regarding its effect as co-substrate for TS (Leary
t al., 1974), which is likely an undesirable property. The unnatural
6S]-isomer is handled by detoxiﬁcation mechanisms after admin-
stration, and the chemical stability of [6R,S]-5,10-methylene-THF
as been shown to be concentration-dependent (Odin et al., 1998).
CoFactor® clinical development programs were initiated, but
ever brought ﬁrm conclusive ﬁndings. There may  have been vari-
us reasons for this, with the route of administration possibly one
uch factor that was never resolved at the time. Studies using intra-
enous bolus injection tended to show positive disease impact, but
ne study relying on intravenous infusion over a more extended
eriod of time did not show the same result (A Vedin, unpub-
ished data: Clinical CoFactor trials meta-analysis, Isofol Medical,
anuary 2015). In this context, the importance of the aforemen-
ioned concentration-dependent stability has never been resolved.
ndeed, the general ﬁeld of therapy with reduced folates may  have
eglected possible important differences between various modes of
dministration and plasma pharmacokinetics/pharmacodynamics
e.g. tissue levels of different fractions), as well as their relation-
hips to therapeutic impact. With recent advances in analytical
echniques, such studies may  now be possible (Odin et al., 2013).
.5. [6R]-5,10-methylene-THF (Modufolin®)
Modufolin® ([6R]-5,10-methylene-THF; Fig. 8) is a biomodula-
or that can directly enhance the desired cytotoxic antitumor effect
f 5-FU. It bypasses the metabolic pathway required by leucovorin.
ith the exception of CoFactor® ([6R,S]-5,10-methylene-THF), all
ther folates need to be activated. Furthermore, the unclear inﬂu-Fig. 8. Chemical structure of Modufolin® ([6R]-5,10-methylene-THF).
ence of equal quantities of unnatural xenobiotics present in the
diastereoisomeric pairs (i.e. leucovorin, mefolinate, and CoFactor®)
is avoided, which is often seen as an advantage by regulatory
authorities.
In patients with colorectal cancer, a direct comparison of
levoleucovorin and Modufolin®, given as equimolar bolus injec-
tions, showed that levoleucovorin produced barely measurable
plasma levels of [6R]-5,10-methylene-THF and [6S]-THF, whereas
Modufolin® resulted in high levels of both within 2 h of injec-
tion (Wettergren et al., 2015). There were high ‘steady-state’
levels of [6S]-5-methyl-THF, for at least 6 h, after administration
of either agent. The bioconversion of levoleucovorin to the active
[6R]-5,10-methylene-THF requires four consecutive steps. It is pos-
sible, however, that following levoleucovorin administration the
relatively slowly formed [6R]-5,10-methylene-THF is quickly con-
sumed by an enzymatic reduction to [6S]-5-methyl-THF in the
blood, whereas following Modufolin® administration the corre-
sponding reduction to [6S]-5-methyl-THF may  be maximized by
enzyme saturation due to the very high concentration of [6R]-5,10-
methylene-THF (Borsi et al., 1990). From this, it is highly probable
that the major effect exerted by levoleucovorin relates to the ulti-
mate re-formation of the active [6R]-5,10-methylene-THF (two
steps) from the generated [6S]-5-methyl-THF pool (i.e. seven steps
from the original levoleucovorin administration). Furthermore, a
several-fold higher tumor concentration of [6R]-5,10-methylene-
THF was  seen 2 h following Modufolin® administration, compared
with levoleucovorin administration, whereas high levels of [6S]-5-
methyl-THF were detected more than 2 h after administration of
either agent. The high [6S]-THF levels in the initial phase follow-
ing Modufolin® administration can be interpreted by a shift of the
association − dissociation equilibrium of [6R]-5,10-methylene-THF
towards [6S]-THF and formaldehyde, by dilution of the injection
solution in the blood.
Activation of folates requires the presence of the relevant
enzymes, which in turn requires high expression of the genes reg-
ulating these enzymes. Patients with colorectal cancer and high
levels of expression of these genes have signiﬁcantly enhanced
disease-free survival when treated with 5-FU plus leucovorin, when
compared with patients with low levels of expression of these genes
(Wettergren et al., 2014). Thus, it may  be speculated that patients
with low folate-related gene expression levels may respond favor-
ably to direct administration of Modufolin®; controlled trials are
needed to conﬁrm this.
9. ConclusionFor many years, folates have been used with cytostatic and
cytotoxic agents to enhance both efﬁcacy and safety. The mech-
anism of action of all folates has been shown to converge on the
ternary complex comprising TS, dUMP, and [6R]-5,10-methylene-
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HF. Modulation of the concentration of this metabolite has been
he central theme in all clinical studies. Application of several of the
recursors is complicated because of the chemical and metabol-
cally unstable nature. This can be improved by changing the
ormulation, while a more effective modulation can perhaps be
chieved by administration of either the active metabolite itself
r a more direct precursor. Another major question for adminis-
ration is the timing, i.e. should the metabolite be given before
r after the cytotoxic drug? For modulation of 5-FU it is generally
greed that the metabolite should be given before 5-FU, although
or capecitabine the metabolite should not be given at the same
ime because of the likelihood of increased toxicity (Schneiders
t al., 2011), and in order to rescue from toxicity leucovorin should
e given after methotrexate (Bertino, 1993). In contrast, in order
o administer pemetrexed safely, folic acid should be started a few
ays before pemetrexed is ﬁrst administered (Chattopadhyay et al.,
007).
Despite the fact that many years have passed since co-
dministration of folates and cytotoxic agents was  ﬁrst introduced,
umerous central questions remain unanswered. Treatment
egimes have become empirically established and have evolved
ver time, often not based on tightly controlled comparisons. This
s partly caused by the nature of the disease and the ensuing
thics. Many important factors have been clariﬁed post hoc and,
ad knowledge been available earlier, other regimes might have
risen.
Actual dosages, pharmacokinetics of folates, modes of adminis-
ration, tissue concentrations, gene proﬁles in normal and tumor
issues, and the relationships between genes, enzyme levels, tissue
olate concentrations, key enzyme inhibition, and clinical outcomes
re all examples of potentially fruitful areas for future scientiﬁc
esearch. With the availability of new analytical and other tech-
iques, as well as new stable folate compounds, it is hoped that
he entire ﬁeld again will be the center of added research focus,
ltimately bringing patients increased clinical beneﬁt.
0. Remark
Product formulations under the registered trademarks Fusilev®,
etafolin®, CoFactor®, and Modufolin® contain different salt forms
f the respective folate. For the sake of clarity, only the term folate
s used to describe the active ingredient.
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